1026 GMT - Genmab's trio of positive late-stage clinical trials mean the Danish biotech company is moving away from a turnaround toward its takeoff, UBS analysts say in a research note. "Genmab has achieved something that is rarely seen in the pharma industry--a highly successful [research-and-development] turnaround," the analysts say. In October, the company reported three very strong late-stage data sets that justified its recent stock rally as each of the drugs has potential to generate more than $7 billion in annual revenue, according to UBS. "We think this is only the start," the analysts add. UBS raises its target price on Genmab to 4,900 Danish kroner from 3,100 kroner. Shares trade 2.4% higher at 3,532 kroner, having gained 74% since the start of 2026.